Evidence map›Paper›PMID 40423299›Full record

Trial reportToxins2025

Single-Dose

Sofia Durán-Hernández, Norma E Herrera-González, Nayar Durán-Hernández, Martha Carnalla, Manuel de Jesús Castillejos-López, Citlaltepetl Salinas-Lara

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sofia Durán-HernándezHospital General Tacuba, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Profesor de Asignatura, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04360, Mexico.ORCID 0009-0002-0492-8386
Norma E Herrera-GonzálezEscuela Superior de Medicina, Instituto Politécnico Nacional (IPN), Mexico City 11340, Mexico.
Nayar Durán-HernándezPitzer Laboratory of Osteoarthritis Research, German Rheumatism Research Center (DRFZ), Leibniz Institute, 10117 Berlin, Germany.ORCID 0000-0003-4253-0387
Martha CarnallaCentro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca 62100, Mexico.
Manuel de Jesús Castillejos-LópezInvestigador, Unidad de Vigilancia Epidemiológica, INER Ismael Cosío Villegas, Mexico City 14080, Mexico.ORCID 0000-0001-8689-9755
Citlaltepetl Salinas-LaraDepartamento de Neuropatología, Instituto Nacional de Neurología y Neurocirugía (INNN), Mexico City 14269, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is the most prevalent rheumatologic disease and a leading cause of years lived with disability worldwide. There are no disease-modifying drugs available to treat it. This study aimed to evaluate the effect of a single dose of 100U botulinum neurotoxin-A (BoNT-A) in patients with early knee OA. We designed a single-arm preliminary clinical trial in patients diagnosed with knee OA (KOA) grades I and II. 45 Patients received a single dose of 100U

Indexed as

Botulinum Toxins, Type ANeuromuscular AgentsOsteoarthritis, KneeAgedFemaleHumansMaleMiddle AgedPain MeasurementTreatment OutcomeBotulinum Toxins, Type AincobotulinumtoxinANeuromuscular Agentsbotulinum toxinscase seriesIncobotulinumtoxinAknee OAosteoarthritispain

Identifiers

PMID40423299
PMCPMC12115587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.